Information That Can Help Define Treatment Options and Make Treatment Decisions for Breast (early-stage and DCIS), Colon and Prostate Cancer Patients
The Oncotype DX diagnostic tests help individualize treatment planning for breast, colon and prostate cancer patients. Patient Stories provide detailed information about patients' experience with Oncotype DX assays.
About the Oncotype DX Breast Cancer Test and Early Stage Breast Cancer
The Oncotype DX breast cancer test, is a test that examines a breast cancer patient's tumor tissue at a molecular level, and gives information about a patient's individual disease. This information can help individualize breast cancer treatment planning and identify options. The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The Oncotype DX gene expression assay is intended to be used by women with early-stage (stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with therapy. Learn more about the Oncotype DX breast cancer test.
About the Oncotype DX Breast Cancer Test for DCIS (Ductal Carcinoma In Situ) and Pre-Invasive Breast Cancer
The Oncotype DX breast cancer test for DCIS patients is the first clinically validated genomic assay to provide an individualized prediction of the 10-year risk of local recurrence (DCIS or invasive carcinoma) to help guide treatment decision-making in women with ductal carcinoma in situ treated by local excision, with or without tamoxifen. Learn more about this test for DCIS patients.
About the Oncotype DX Colon Cancer Test and Stage II and Stage III Colon Cancer
The Oncotype DX Colon Cancer test is an advanced diagnostic test that has been clinically validated for the assessment of risk of recurrence in stage II and stage III colon cancer from three prospectively-designed studies 1, 2, 3. This multigene test examines a colon cancer patient's tumor at a molecular level, in order to provide information about the individual biology of each tumor. The Oncotype DX test does this by evaluating specific genes within the colon tumor to determine the likelihood that the cancer cells will spread and thus cause colon cancer recurrence following surgical resection. The information provided by the Oncotype DX test has been shown to have independent value beyond currently used measures for determining colon cancer recurrence risk. For people recently diagnosed with stage II and stage III colon cancer, the Oncotype DX test may be an appropriate part of treatment planning. For detailed information about the Oncotype DX Colon Cancer test, please visit the Oncotype DX product website.
About the Oncotype DX Prostate Cancer Test and Early-Stage Prostate Cancer
The Oncotype DX prostate cancer test is a standardized, validated biopsy-based test that measures the level of expression of multiple genes across multiple pathways that predict aggressive prostate cancer, overcoming issues related to tumor heterogeneity, biopsy under-sampling and under-staging to substantially improve individualized risk assessment at diagnosis, prior to treatment intervention. Further, the Oncotype DX prostate cancer test allows men with apparent low-risk disease who are identified to harbor higher risk features to have greater confidence in the decision to undergo potentially curative therapy. Based on the biology of each individual cancer, the information provided by the Oncotype DX prostate cancer test can help patients and doctors determine the most appropriate treatment. Learn more about the Oncotype DX prostate cancer test. To learn more about the Oncotype DX tests for DCIS, breast, colon and prostate cancer please visit the Oncotype DX product website or call Tel: +1 (888) ONCOTYPE
Learn more about Genomic Health’s product development activities.
- Gray RG, Quirke P, and Handley K. Validation study of a quantitative multi-gene RT-PCR assay for assessment of recurrence risk in stage II colon cancer patients. J Clin Oncol. 2011; 29: 4611-9.
- Venook AP, Niedzwiecki D, Lopatin M, et al. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. Poster presented at the ASCO Annual Meeting; 2011; Chicago, IL.
- O'Connell MJ, Lee M, Lopatin M, et al. Validation of the 12-gene colon cancer Recurrence Score result in NSABP C-07 as a predictor of recurrence in stage II and II colon cancer patients treated with 5FU/LV (5FU) and 5FU/LV + oxaliplatin (5FU+Ox). Poster presented at the ASCO Annual Meeting; 2012; Chicago, IL.